Modest growth expected for Asia-Pacific ovarian cancer drug market

30 January 2015

The Asia-Pacific (APAC) therapeutics market for ovarian cancer (OC) will undergo a modest rise in value, from $294.3 million in 2013 to $417.6 million by 2020, expanding at a compound annual growth rate (CAGR) of 5.1%.

According to business intelligence provider GBI Research’s latest report, Japan held the largest share of the regional OC therapeutics space in 2013, with 62%, followed by China with 16.5%. The other markets making up the APAC region are Australia and India.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >